Weekly insulin: a paradigm shift in type 1 diabetes therapy

Affiliations

¹ Cincinnati Children's Hospital Medical Center, Cincinnati OH 45229, USA; The University of Cincinnati, Department of Pediatrics, Division of Endocrinology, Cincinnati OH 45229, USA. Electronic address: amy.shah@cchmc.org.
² Department of Pediatrics, Division of Pediatric Endocrinology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Comment

Amy S Shah et al. Lancet. 2023.

. 2023 Nov 4;402(10413):1598-1599.

doi: 10.1016/S0140-6736(23)02227-4. Epub 2023 Oct 17.

¹ Cincinnati Children's Hospital Medical Center, Cincinnati OH 45229, USA; The University of Cincinnati, Department of Pediatrics, Division of Endocrinology, Cincinnati OH 45229, USA. Electronic address: amy.shah@cchmc.org.
² Department of Pediatrics, Division of Pediatric Endocrinology, Johns Hopkins School of Medicine, Baltimore, MD, USA.

No abstract available

Comment on

Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial.
Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, Mathieu C, Rosenstock J, Woo V, Klonoff DC. Russell-Jones D, et al. Lancet. 2023 Nov 4;402(10413):1636-1647. doi: 10.1016/S0140-6736(23)02179-7. Epub 2023 Oct 17. Lancet. 2023. PMID: 37863084 Clinical Trial.